UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~April 96, 2010

~~STEM~~AMSTEM ~~CELL~~CORPORATION ~~THERAPY INTERNATIONAL, INC.~~

(Exact Name of Registrant as Specified in Its Charter)

Nevada

000-51931

88-0374180

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

13406 Racetrack Road #233, Tampa, FL 33626

(Address of principal executive offices – zip code)

(813) 283-2556

(Registrant’s telephone number, including area code)

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

ITEM 5 2.02 ~~ELECTION~~RESULTS OF ~~DIRECTOR~~OPERATIONS ORAND ~~PRINCIPAL~~FINANCIAL ~~OFFICER~~ CONDITION

~~TAMPA~~AmStem Corporation (AMST, ~~Fla.~~or –“the ~~February 9~~Company”), ~~2010~~announced –the ~~Stem~~financial ~~Cell~~results ~~Therapy~~for ~~International~~its 90% owned subsidiary, ~~Inc.~~Histostem, ~~(OTCBB:~~for ~~SCII)~~the ~~announced~~year ~~that~~ended ~~Dr.~~December ~~Hoon~~31, ~~Han~~2009. ~~has~~A ~~been~~copy ~~elected Chairman~~ of the ~~Company’s~~release ~~Board~~is ofattached ~~Directors~~as ~~effective~~Exhibit ~~immediately~~99.1.

The ~~Company~~information ~~also~~furnished ~~announced~~herein, ~~the~~including ~~resignation~~Exhibit 99.1, is not deemed to be “filed” for purposes of ~~Lixian~~Section 18 ~~(John)~~of ~~Jiang from~~the ~~all~~Exchange ~~positions~~Act, ~~with~~or otherwise subject to the ~~Company~~liability of that section. This ~~Lixian~~information ~~(John)~~will ~~Jiang~~not ~~continues~~be deemed to be ~~interested~~incorporated inby ~~assisting~~reference into any filing under the ~~Company~~Securities inAct anor ~~advisory~~the ~~capacity~~Exchange ~~when~~Act, except to the ~~Company~~extent ~~forms~~that ~~its~~the ~~medical~~registrant ~~advisory~~specifically incorporates ~~committee~~them by reference.

DrITEM 7. ~~Hoon~~01 ~~Han~~REGULATION ~~has~~FD ~~been appointed to the Board of Directors until his respective successor is elected and qualified or until his earlier resignation, removal from office or death.~~ DISCLOSURE

~~Dr. Han is the President and Chief Executive Officer of HistoStem Co., Ltd. where he established the first~~AmStem ~~cord~~Corporation ~~blood bank~~(AMST, ~~the~~or ~~first bone marrow bank and~~ “the ~~first stem cell bank in Korea. Among his career highlights~~Company”), ~~Dr. Han~~announced ~~has successfully performed a bone marrow transplant between a father and son; he has conducted research proving~~ the ~~existence~~ offinancial ~~stem~~results ~~cells in cord blood and he has developed a cure~~ for ~~intractable~~its ~~diseases~~90% ~~such~~owned assubsidiary, ~~Buerger’s disease using cord blood stem cells. Dr. Han holds a PhD and an MD from the Catholic Medical University in Seoul~~Histostem, ~~Korea~~for ~~and he has served as a research professor at~~ the ~~University~~year ofended ~~Southern California Los Angeles~~December 31, ~~as well as at the Catholic Medical University~~2009. HeA iscopy ~~the Vice President~~ of the ~~Institution~~release ofis ~~Medical~~attached ~~Science,~~as ~~Catholic~~Exhibit ~~Medical University; the Chairman of the Korea Society for Biomaterials and a member and director of Experimental Hematology~~99.1.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

Exhibits

99.1 Press release dated ~~February 9~~April 5, 2010.

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~STEM~~AmStem ~~CELL~~Corporation ~~THERAPY INTERNATIONAL, INC.~~ By: /s/ Andrew J. Norstrud Name: Andrew J. Norstrud Title: Chief Financial Officer

Date: ~~February~~April 96, 2010

Filing Compare · AmStem Corp